论文部分内容阅读
目的评价肝动脉化疗栓塞术联合索拉非尼治疗晚期不可切除肝癌的疗效。方法 12例肝动脉化疗栓塞术联合索拉非尼治疗的晚期不可切除肝癌患者作为实验组,同时选出年龄段相同并只接受肝动脉化疗栓塞术的晚期不可切除肝癌患者42例作为对照组。比较两组的总有效率、临床获益率、中位无进展生存期(PFS)和中位总生存时间(OS)。结果两组总有效率分别为42%和38%,临床获益率分别为75%和71%,差异无统计学意义(P>0.05);PFS分别为8个月和5.1个月;OS分别为16个月和9.3个月。中位PFS和中位OS比较差异有统计学意义(P<0.05)。结论肝动脉化疗栓塞术联合索拉非尼治疗晚期不可切除肝癌与单纯使用肝动脉化疗栓塞术相比预期生存更长。
Objective To evaluate the efficacy of transcatheter arterial chemoembolization combined with sorafenib in the treatment of advanced unresectable liver cancer. Methods Twelve patients with advanced unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib and 42 patients with advanced unresectable hepatocellular carcinoma (HCC) who were the same age group and underwent transcatheter arterial chemoembolization were selected as the control group. The total effective rate, clinical benefit rate, median progression-free survival (PFS) and median overall survival (OS) were compared between the two groups. Results The total effective rates were 42% and 38% in the two groups, and the clinical benefit rates were 75% and 71% respectively, with no significant difference (P> 0.05); PFS was 8 months and 5.1 months respectively; For 16 months and 9.3 months. The median PFS and median OS were significantly different (P <0.05). Conclusion Transcatheter arterial chemoembolization combined with sorafenib in the treatment of advanced unresectable hepatocellular carcinoma is expected to survive longer than simple transcatheter arterial chemoembolization.